Phoenicia Scientists were awarded a new US patent (8,759,378, Issued June 24, 2014: “Methods for Treating Blood Disorders”), covering newly-discovered small molecules which regulate fetal globin production for the treatment of β-thalassemia and sickle cell disease
A virus-targeted therapy for
Epstein Barr virus associated lymphomas
Phoenicia is working to bring an innovative therapeutic approach for deadly EBV-associated lymphomas into clinical trials with a new generation and oral virus-targeted therapeutic.
Phoenicia Founder Douglas V. Faller developed a method to activate silent genes within the dormant EBV virus, which resides in lymphoma cells.
The EBV virus, whether a “passenger” or the cancer-causing agent, can then serve as a target for therapeutics. Activating the viral TK gene causes activation of a common antiviral pro-drug, selectiving killing the lymphoma cells containing the virus. Continue reading
NIH grant to convert a potent IV
therapy for refractory wounds into
a topical formulation
Phoenicia has received a new small business grant from the National Institutes of Health for studies to convert an intravenous therapy which healed refractory, disabling leg ulcers in hemolytic anemias, sickle cell disease and β-thalassemia, into a topical preparation which can be used readily by patients world-wide. Continue reading
The mission of Phoenicia Biosciences is to advance the development and translation of therapies for serious medical conditions for which current treatments are inadequate or lacking, particularly diseases affecting global populations.